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Abstract
Epistatic interactions between residues determine a protein’s adaptability and shape its
evolutionary trajectory. When a protein experiences a changed environment, it is under
strong selection to find a peak in the new fitness landscape. It has been shown that
strong selection increases epistatic interactions as well as the ruggedness of the fitness
landscape, but little is known about how the epistatic interactions change under
selection in the long-term evolution of a protein. Here we analyze the evolution of
epistasis in the protease of the human immunodeficiency virus type 1 (HIV-1) using
protease sequences collected for almost a decade from both treated and untreated
patients, to understand how epistasis changes and how those changes impact the
long-term evolvability of a protein. We use an information-theoretic proxy for epistasis
that quantifies the co-variation between sites, and show that positive information is a
necessary (but not sufficient) condition that detects epistasis in most cases. We analyze
the “fossils” of the evolutionary trajectories of the protein contained in the sequence
data, and show that epistasis continues to enrich under strong selection, but not for
proteins whose environment is unchanged. The increase in epistasis compensates for the
information loss due to sequence variability brought about by treatment, and facilitates
adaptation in the increasingly rugged fitness landscape of treatment. While epistasis is
thought to enhance evolvability via valley-crossing early-on in adaptation, it can hinder
adaptation later when the landscape has turned rugged. However, we find no evidence
that the HIV-1 protease has reached its potential for evolution after 9 years of adapting
to a drug environment that itself is constantly changing. We suggest that the mechanism
of encoding new information into pairwise interactions is central to protein evolution
not just in HIV-1 protease, but for any protein adapting to a changing environment.
Author Summary
Evolution is often viewed as a process that occurs “mutation by mutation”, suggesting
that the effect of each mutation is independent of that of others. However, in reality the
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effect of a mutation often depends on the context of other mutations, a dependence
known as “epistasis”. Even though epistasis can constrain protein evolution, it is
actually very common. Such interactions are particularly pervasive in proteins that
evolve resistance to a drug via mutations that create defects, and that must be repaired
with compensatory mutations. We study how epistasis between protein residues evolves
over time in a new and changing environment, and compare these findings to protein
evolution in a constant environment. We analyze the sequences of the human
immunodeficiency virus type 1 (HIV-1) protease enzyme collected over a period of 9
years from patients treated with anti-viral drugs (as well as from patients that went
untreated), and find that epistasis between residues continues to increase as more
potent anti-viral drugs enter the market, while epistasis is unchanging in the proteins
exposed to a constant environment. Yet, the proteins adapting to the changing
landscape do not appear to be constrained by the epistatic interactions and continue to
manage to evade new drugs.
Introduction
The interactions between the residues within a single protein (within-protein
epistasis [1]) often determine the structure and function of the protein [2–4].
Understanding these epistatic interactions is important because they shape the protein
fitness landscape and thus guide the evolution of a protein given its genetic
background [5,6]. At the same time, the environment influences the fitness effects of
mutations and their epistatic interactions, and a change in the environment changes the
topography of the fitness landscape as well as the epistatic effect of mutations [7]. A
typical example of a changing environment for a protein is the introduction of drugs to
counteract a pathogen. In that case, a drug-resistance mutation that is beneficial in a
drug environment might have a significant fitness cost in the absence of drugs [8, 9].
Even in the drug environment, resistance mutations can incur fitness costs that are
mitigated by compensatory mutations, and these fitness-restoring mutations are selected
together with the resistance mutations if the fitness of the resulting protein exceeds that
of the wild-type in the drug-environment [10]. Other compensatory mutations act by
re-stabilizing the protein and preventing misfolding or proteolysis [11–13], while
sometimes resistance mutations partly compensate each other’s deleterious effects [14].
Moreover, compensatory mutations can appear before resistance mutations if they are
not deleterious on their own, paving the way for resistance mutations to appear without
incurring significant fitness costs [15–17]. Epistatic interactions have been implicated in
the evolution of drug resistance in many pathogens, including influenza, malaria,
Escherichia coli, tuberculosis, and Chlamydomonas reinhardtii [14, 18–20].
To understand the long-term evolution of a protein in a dynamic environment in
which the selection pressure is persistent, evidence of epistatic interactions at multiple
time points is needed as the fitness landscape changes over time with the environment.
Previous investigations of the impact of epistasis on evolutionary outcomes analyzed
epistatic interactions in the absence or presence of a selection pressure at a single time
point, showing that epistatic interactions can facilitate adaptation [21–28]. In particular,
computational analyses of HIV fitness landscapes derived from statistical models
showed that these landscapes have high neutrality as well as ruggedness, suggesting
high potential for epistatic interactions [23]. Further, an analysis of in vitro virus fitness
measurements from more than 70,000 patients revealed that epistasis explained more
than half of the variance in fitness measurements, highlighting the importance of
epistasis in the HIV-1 fitness landscape [24].
While these studies emphasize the importance of epistasis in adaptive evolution, here
we analyze how epistatic interactions themselves change over time. We focus on the
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Human Immunodeficiency Virus-1 (HIV-1) protease, a small protein necessary for the
production of mature and infectious HIV-1 particles. The HIV-1 protease is a
homodimer of two 99 residue chains, and it cleaves the viral polyprotein into active
components that are necessary for virus maturation [29]. Because an inactive protease
results in uninfectious viruses, the protease was one of the first targets of anti-retroviral
drugs. However, due to its high mutation rate (about 0.3 mutations per genome per
generation [30]), HIV-1 quickly evolves resistance to those drugs. These resistance and
compensatory mutations, as well as the covariation between residues in HIV-1’s protease
are well studied [31–33].
The evolutionary trajectory of resistance to protease inhibitors is extremely complex.
When the virus is first exposed to the changed fitness landscape containing the
inhibitor, viral count drops to undetectable levels [34], as the fitness peak that the viral
population occupied in the no-drug fitness landscape is erased. However, some minority
variants in the untreated viral population might still possess replicative capacity in the
drug environment (albeit much reduced), forming the seeds of drug resistance [35].
Indeed, most well-known resistance mutations are associated with significant fitness
costs [10,36], so that at the onset of resistance the viral populations are likely still
significantly smaller than in untreated individuals. However, mutations that
compensate for the fitness defects will readily emerge. While these compensatory
mutations can either maintain or reduce viral fitness if they occur on their own, they
usually restore the fitness cost of the resistance mutation to some extent, and as a
consequence form an epistatic pair with the resistance mutation. Note that the residues
that are coupled in the treatment landscape are unlikely to be coupled in the absence of
treatment, implying that it is the adaptation to the new landscape that forces the
interaction. Once compensatory mutations have restored viral fitness, viral populations
return to pre-drug levels and can search for more compensating mutations [37].
Exposure to second-line drugs (given to patients that have evolved resistance) repeats
the cycle, leading to more resistance mutations [38], followed by compensatory
mutations that are epistatically linked with them.
As more and more resistance mutations accumulate, loss of thermodynamic stability
becomes more and more acute, and compensatory mutations are selected that
re-stabilize the protein. While stabilizing mutations are not selected against individually
when they occur on their own (compensatory mutations often have a fitness advantage if
they occur in the absence of treatment [39]), several stabilizing mutations together can
be undesirable as they decrease protein variability and therefore can impede
evolvability [40,41]. Since epistasis and ruggedness are coupled [25,42, 43], the repeated
emergence of resistance mutations and selection for compensatory mutations that
interact epistatically with those resistance mutations results in a protein that finds itself
in an increasingly rugged fitness landscape.
We hypothesize that a strong selection pressure of treatment increases the epistatic
interactions in the long-term evolution of HIV-1 protease, allowing the protein to realize
its evolutionary potential. To test this hypothesis, we compare the HIV-1 protease
sequences from patients treated with anti-retroviral drugs to protease sequences from
untreated patients, collected over a nine year period. This wealth of publicly available
data provides an unprecedented opportunity to study the adaptive evolution of a
protein in an environment with persistent (perhaps even increasing) selection pressures
due to the continued introduction of new drugs as opposed to a protein evolving in the
absence of these selection pressures.
Epistatic interactions between mutations are usually deduced by measuring the
fitness effect of the single site mutations as well as the double-mutant. However,
obtaining evidence of changes in epistasis over a long enough period of time is
challenging when viral fitness has to be assayed. Here we use the mutual (shared)
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information between protein loci (residues) as a proxy for epistasis. Briefly, information
shared between sites is a measure of covariation between the sites, so that knowing the
residue at one site makes it possible to predict the residue at the covarying site with
accuracy better than chance [44]. Thus, information constrains the context of a residue,
in the same manner that epistasis constrains the fitness effect of a mutation in the
presence of another. Using information as a proxy for epistasis is not a new idea (see,
e.g., [45] and references cited therein, as well as [46] for an application to gene
networks). However, the relationship between epistasis and information is not
one-to-one. As a consequence, it is possible that two residues interact epistatically but
show no information. Conversely, if two residues have positive information, they must
interact epistatically, at least in a model without spatial effects and infinite population
size. Thus, information is a sufficient (but not a necessary) condition for epistasis. We
have analyzed the relationship between epistasis and information in random fitness
landscapes of two interacting loci, and found that in less than 30% of cases would a pair
of loci be epistatic while showing negligible information (see below). Furthermore, those
pairs that showed little information also predominantly showed little epistasis.
Keeping in mind this limitation, studying pair-wise information (which can be
deduced from sequence data) instead of epistasis (which cannot) allows us to use the
wealth of time-course sequence data of a protein to study its long-term evolution. Not
that residue covariation in the protease can in principle be due to population subdivision
rather than epistasis [47], which would be reflected in a deeply branched phylogenetic
structure. However, it turns out that deep branches are rare in HIV-1 phylogeny.
Indeed, using sequence data from the HIV Stanford Database, Wang and Lee show that
amino acid covariation in HIV-1 protease sequences is largely due to selection pressures
and not due to background linkage disequilibrium [48]. We corroborate this and find
that protease sequences from the same database assume a star-like phylogeny (S1 Text),
supporting the notion that any observed residue covariation is largely due to selection
pressures and not due to population subdivision and other phylogenetic factors.
We first show how the persistent selective pressure of a drug environment increases
residue variability over time, and document changes in physico-chemical properties due
to these residue substitutions that suggest non-neutral evolution. We then show that
epistatic interactions are enriched over time in the protein undergoing continuous
adaptive evolution in the presence of drugs, but not in proteins where the environment
remained constant. This leads us to conclude that while selection pressures increase
per-site residue variability–and thus reduce information stored at each protein locus on
average–the information stored in higher-order interactions increases over time.
Results
High selection pressure increases residue variability at multiple
loci in the HIV-1 protease
To compare the long-term adaptation of the HIV-1 protease in the presence and absence
of selection pressure of treatment, we analyzed the protease sequences collected in the
years 1998-2006 from patients that did not receive treatment (untreated group), as well
as from patients that received treatment (treated group, see Materials and Methods).
The per-site entropy (a measure of sequence variation) for each of the 99 positions
shows that some protease positions are highly variable even in the absence of treatment,
thus indicating some degree of neutrality. However, many more loci become variable
(entropic) upon treatment (Fig 1, see S2 Text for sequence logos of untreated and
treated protease sequences averaged over all years). Moreover, several loci in the protein
had higher entropy in 2006 compared to 1998, hinting at an increase in per-site residue
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variability over the years, especially in the treated data set (see also S1 Fig, which
shows entropy differences for all years for both the treated and untreated group).
The increased variability per site might seem counter-intuitive from the point of view
of population genetics, where adaptation results in substitutions that lead to reduced
diversity from hitchhiking [35]. While such reduced diversity is possible in the short
term, we caution that due to the high mutation rate of HIV, pre-treatment diversity can
be re-established fairly quickly after drug resistance has emerged. This rebound in virus
titer further allows the virus to find mutational paths to resistance. However, it is also
possible that some of the observed variability is due to the stochastic mixing (within the
database) of many populations that each took diverse paths to resistance. Some
positions in the untreated group also show higher residue variability at the later time
point, and this is likely due to transmission of drug-resistant virus to untreated
individuals via new infections [49–51]. However, this background signal remains low due
to the reduced selection pressure in the untreated group.
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Figure 1. Average per-site entropies at every position of the HIV-1
protease. Untreated (top panel) and treated (bottom panel) datasets at the earliest
(year 1998, red) and latest (year 2006, blue) time point of our analysis. 300 sequences
are resampled from data for each year and average entropy for each position is
calculated from the entropies in 10 resampled datasets. Site-specific variation generally
increased across the protein following treatment. Entropy (variability) also increased
from 1998 to 2006 for several positions. Error bars denote ±1 SE.
Increased residue variability due to treatment mirrors
physico-chemical changes in the protein
A closer look at the protease positions with increasing residue variability reveals that
the protein loci that have undergone a marked increase in variation have been previously
associated with drug resistance (Figure 2 top panel) [52]. Position 63 is the only site
that becomes significantly less variable upon treatment. Many of the changes in entropy
at each position correlate well with physico-chemical changes (such as changes in the
iso-electric point pI or in the residue weight) at those positions (Spearman correlation
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coefficient between absolute values of entropy difference and pI difference: R = 0.738,
p = 2.95× 10−18; Spearman R between absolute values of entropy difference and residue
weight difference: R = 0.819, p = 3.52× 10−25) suggesting that these changes are
adaptive and influence the function of the protein in its new environment (see S3 Text
and Fig 2, middle and lower panels). Leucine at position 10 is substituted by the
slightly heavier isoleucine, a compensatory mutation showing a slight increase in residue
weight difference (Fig 2, bottom panel, L10I is a compensatory mutation as shown
in [52,53]); lysine is replaced by a more basic arginine residue at position 20, another
compensatory mutation as arginine can form more electrostatic interactions compared
to lysine and thus enhances protein stability [52, 54]; and aspartic acid is substituted by
the uncharged asparagine at position 30, a strong resistance mutation [52,55]. While
the residue physico-chemical properties discussed here are not exhaustive, the significant
positive correlation between changes in these properties and changes in residue
variability suggest that the residue variation brought about by treatment is non-random.
Epistatic interactions between residues increase following
treatment
Information about a protein’s environment is stored not only in individual residues of
the protein, but also in the manner in which these residues interact epistatically. We
estimate the information the protein stores about its environment in two ways: one that
considers explicitly the information stored at each position in the protein independent of
other sites (I1), and the measure I2 that in addition to I1 includes the mutual
information between every pair of positions (see Materials and Methods).
An increase in entropy per site corresponds to a decrease in per-site information (I1).
We find that the I1 for treated protease sequences is consistently lower that that of
untreated sequences, indicating high sequence variability in the treated data (Figure 3,
top panel). The slopes for the treated and untreated I1 data are not significantly
different, suggesting that although the treated data has higher sequence variability, this
variability does not increase significantly over the years. However, the sum of mutual
information of all pairs of positions (the component of information due solely to
pair-wise interactions) gradually increases, suggesting that epistatic interactions become
enriched over time (Fig 3, middle panel, slopes for treated and untreated data are
significantly different, p ≤ 0.001). Fig 4 shows a gradual increase in pairwise mutual
information between protease positions due to treatment (bottom panel), while pairwise
mutual information in the untreated group remains low over the years (top panel). As
discussed, adding the sum of pairwise mutual information to I1 gives I2, which thus
measures the information stored in the protein taking into account the pairwise
dependencies between positions in addition to per-site variability (Fig 3, bottom panel,
slopes for treated and untreated data are not significantly different). We find that I2
remains relatively constant over the years and converges to the same value in the
treated as well as untreated data despite increase in residue variability and enrichment
of epistatic interactions in the treated data. Such a finding may at first appear
surprising, but Carothers et al. showed that the functional capacity of biomolecules
(RNA aptamers in their study) correlated with the information contained in the
sequence, and that functionally equivalent biomolecules had similar total information
content [56]. Our analysis thus suggests that the similar total information content for
proteins in the treated and untreated case reflects similar functional activity, achieved
in the treated group by increasing epistasis that compensates for the information loss
due to increased sequence variability. The increase in epistasis thus allows the protein to
adapt and attain high fitness (via wild-type level biological activity), in the increasingly
rugged fitness landscape of treatment.
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Figure 2. Changes in protease entropy and physico-chemical properties.
Changes in per-site entropies (top panel), residue isoelectric point (middle panel), and
residue weights (bottom panel) due to treatment. The property difference at each site is
obtained by subtracting property (entropy/pI/residue-weight) value of the untreated
data from that of the treated data. Average values are obtained by sampling sequence
data from all years (1998-2006, 10 subsamples/year of 300 sequences each). Error bars
represent ±1 SE. Red dots represent positions known to be primary drug resistance loci,
while black dots mark positions of compensatory or accessory mutations [52].
Resistance loci are shaded in red and accessory loci are shaded in black.
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Besides a trend in the overall strength of epistatic interactions in the treated group,
we also find that the spatial organization of interactions in the protein is modified. In
S5 Text, we show that untreated subjects stored more information in distant pairs early
(1998, distant: residue distance ≥ 8A˚), a trend that is reversed in 2002.
Figure 3. Estimates of the information content of the HIV-1 protease.
Filled black circles represent data from untreated subjects and blue triangles represent
data from treated individuals. I1 [see Eq. (12)] is consistently low in treated sequence
data over the years, indicating high sequence variability in the drug environment (top
panel). The middle panel shows that the sum of pairwise mutual information
significantly increases upon treatment (p ≤ 0.001). On adding the sum of pairwise
mutual information to I1, we obtain a comprehensive measure of information that
considers pairwise interactions between residues [I2, Eq. (13)]. I2 for both the treated
and untreated data is comparable and unchanging over the years. We use data only for
positions 15-90, as residues 1-14 as well as 91-99 have missing sequence data leading to
error-prone estimates of entropy, as evidenced in S2 Fig. Error bars represent ±1 SD.
As pairwise mutual information is a proxy for epistasis (Materials and Methods), the
significant temporal increase in mutual information suggests that epistatic interactions
are crucial for the protease to adapt in a dynamic drug environment. In contrast, the
sum of pairwise mutual information remains fairly constant in the drug-free
environment (Fig 3, middle panel). It should be noted that most of the treated data for
year 2003 came from two phase-III clinical trials that focused on the 2nd-line
anti-retroviral drug tipranavir (2900 out of 3399 sequences) [57]. Resistance to
tipranavir requires accumulation of several mutations, more than the mutations required
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Figure 4. Increase in epistasis in HIV-1 protease over time. Pairwise
interactions in the HIV-1 protease are shown for years 1998, 2002, and 2006 in the
drug-free (top row) and drug environment (bottom row). Each heatmap shows the
mutual information for each pair of residues. Pairwise information (and thus epistatic
effects) are fairly constant in the drug-free environment, but gradually increase in the
treated group.
for the 1st-line protease inhibitors, and this higher genetic barrier to resistance makes it
suitable for salvage therapy for patients already experiencing resistance to other drugs.
The substantial decrease in I1 for the year 2003 thus can be attributed to an increased
entropy as a consequence of accumulating a higher number of mutations required for
resistance to tipranavir. It is curious that the marked increase in variability in the
tipranavir-dominated data set is not associated with a marked increase in pair-wise
information (compared to the adjacent years), suggesting that the tipranavir-induced
mutations are mostly non-epistatic.
Pairwise interactions between amino acids are thought to be sufficient to encode the
protein fold, and thus pairwise interactions can be considered as a sufficient source of
protein functional information [58]. While there is currently no evidence that
higher-order interactions between residues are important, some authors have discussed
this issue [59]. Mapping the high information loci (interactions of a strength of at least
0.1 bits) on the protease structure for the treated group for the first year (1998) and
comparing them to the treated group in 2006 (Fig 5) clearly shows the increase in
epistatic connections in the latter time point.
The observation that strong selection due to treatment increases residue variability
(thus decreasing I1) while increasing epistatic interactions in the protease (as measured
by pairwise mutual information) is corroborated by a longitudinal analysis of
information measures in protease sequences from patients who were untreated at the
first time point and received treatment at the second time point (see S4 Text).
Discussion
It is difficult to predict the evolutionary trajectory of a protein from fitness effects of
mutations along with mutation rate and population size, but we can trace the
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Figure 5. Epistatic interactions mapped onto the protease structure.
Epistatic interactions in the protease sequences in treated data from the year 1998 (red
on the left chain) and 2006 (blue, right chain). The interacting residues are numbered.
Only those interactions are shown where information is greater than 0.1 bits, indicating
strong epistasis. Figure generated using Chimera [60].
evolutionary history of a protein to understand the processes underlying its long-term
evolution. While evolution experiments with bacteria, viruses, and yeast provide direct
evidence for evolution-in-action, enabling the study of various aspects of evolutionary
dynamics as well as the likelihood of certain evolutionary paths [61–63], indirect
evidence such as sequence data collected over years can be a valuable resource to retrace
the evolutionary steps taken by a protein on an adaptive fitness landscape over a long
period of time. The sequences of the HIV-1 protease are one such resource that contain
the “fossils” of the evolutionary trajectory (albeit in a statistical form) of the protein.
Although this sequence data comes from isolates collected from different patients over
the years, the star-like phylogeny observed for data from each year indicates the absence
of population subdivisions and linkage disequilibrium that might have confounded the
information-theoretic analysis we present here (S1 Text). It is likely that each sequence
in the data represents the major HIV-1 variant circulating in each patient. If the viral
populations within the hosts have not yet reached equilibrium (if such an equilibrium
exists in the presence of persistent selection pressures of host immune response and
treatment), the sequence obtained from treated individuals will not contain all of the
resistance and compensatory mutations that might be found at the equilibrium. Thus,
the information-theoretic measures computed here represent a lower bound of the true
sequence variability and epistatic interactions present in a within-host viral population.
We have investigated the long-term evolution of a protein by computational analysis
of HIV-1 protease sequences from treated and untreated patients collected over a span
of nine years (1998-2006), and find that the molecule responds to the selection pressures
of treatment by accumulating mutations that confer drug resistance. At the same time,
several positions in the protease show considerable neutrality even in the absence of
treatment (Figure 1). Indeed, a complete mutagenesis of the protease showed that
several sites are insensitive to mutation in the absence of a selection pressure, and thus
appear neutral [64]. Yet, some of those neutral mutations often appear in tandem with
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known resistance mutations, possibly compounding the fitness effects of the resistance
mutations [65]. Even known resistance mutations usually do not confer resistance in
isolation, but require compensatory mutations before resistance is achieved [53].
Because on average a mutation destabilizes the protein fold by about 1 kcal/mol,
proteins cannot accumulate multiple resistance mutations without running the risk of
thermal instability [11]. Yet, HIV-1 protease with resistance to multiple drugs can
accumulate more than 10 mutations [66–68]. We suspect that many of these mutations
are re-stabilizing the protein,thus compensating for the fitness cost of resistance
mutations [12,13]. In addition, sequence logos of protease sequences from untreated
patients (S2 Text) shows that several resistance and compensatory mutations are
present at low frequencies prior to treatment, suggesting that pre-existing compensatory
mutations may protect the protein from incurring the potentially strong fitness costs of
resistance mutations. We show that as sequence variability increases due to treatment,
more and more of the variable residues interact with other residues, leading to an
increase in the epistatic interactions. Along this evolutionary trajectory, the protein
finds itself in a fitness landscape that is increasingly rugged [23].
That the ruggedness of the fitness landscape has significant effects on the evolution
of a protein has been discussed extensively [25,43,69–72]. These studies suggest that
epistasis can have either an inhibitory or an accelerating effect on evolutionary
trajectories, determined mainly by whether evolution occurs far off the fitness peak or
close to it. Computational simulations of evolutionary adaptation reveal that while
increased epistasis correlates with high ruggedness in the fitness landscape, evolvability
(the ability to attain the highest fitness peak) declines beyond a threshold epistasis [25].
The sign of epistasis (positive vs. negative epistasis) also can affect the speed of
adaptation. Epistasis is positive (or negative) when the fitness effect of the double
mutant is greater (or smaller) than the sum of the fitness effects of individual mutations.
Negative epistasis between beneficial mutations is often associated with diminishing
returns in climbing a single peak [26,73–75], while positive epistasis is associated with
compensatory effects [76] that can enhance crossing of valleys between peaks [25,77].
Computational studies further clarify that positive epistasis accelerates evolvability,
while negative epistasis promotes robustness [78]. However, if the landscape is too
rugged, the reciprocal sign epistasis between mutations may prevent valley crossing [79].
As we cannot determine the sign of epistasis using our information-theoretic methods,
we are unable to verify that the epistasis between mutations in the HIV-1 protease is
mostly positive, as suggested by Bonhoeffer et al. [80].
We find here that as epistasis between residues in the protease continues to increase
(as revealed by the monotonically increasing sum of pairwise mutual information),
epistasis is still contributing to adaptation rather than inhibiting it. However, there is
little doubt that evolution in a more and more rugged fitness landscape will have a
significant impact on evolvability. For example, it is known that some compensatory
mutations that repair fitness costs increase viral fitness in the absence of drugs [39].
These mutations are found in individuals who have transmitted drug resistance, but
they are not common in the treatment-naive HIV-1 population. One suggestion is that
the evolutionary pathway to this polymorphism is simply too complex to emerge de
novo [81], suggesting that the virus has evolved into a region of genetic space from
which there is no return.
Previous studies of epistatic interactions in adaptive evolution emphasized their
importance for adaptation [2, 14,18,20,21,26,82]. Our analysis provides statistical
arguments about the changes in epistatic interactions during long-term adaptation of a
protein in an environment of persistent high selective pressure. Ideally, the present
findings should be corroborated by longitudinal studies that collect sequence or fitness
data regularly and for an extended period of time. Such studies would significantly
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contribute to and understanding of the impact of strong selection pressures and
continually changing landscapes on adaptive evolution.
Materials and Methods
HIV-1 Protease sequences
The protease sequences for HIV-1 subtype B were collected from the HIV Stanford
database [http://hivdb.stanford.edu] on September 17, 2013. The database collects
sequences from pilot studies and clinical trials that are published with sequence data
deposited in GenBank. We only used sequences for which the exact dates for isolate
collection are known (as opposed to guessed from the time of publication or clinical
trials).
We focused our analysis on 18,571 sequences from the years 1998 to 2006, in which
more than 300 protease sequences are available for both treated and untreated sequence
datasets (Tab 1). Since these data come from different sources, they are not
longitudinal. Sequences obtained from patients receiving ≥ 1 protease inhibitors are
labeled as treated, while sequences from patients not receiving any protease inhibitors
are labeled as untreated. Note that a fraction of new infections have transmitted
drug-resistance, and thus even higher sequence diversity (≈8% of new cases had
transmitted drug-resistance by January 2007 [83]). Since the HIV Stanford database
does not keep data on transmitted drug-resistance for treatment-naive individuals, we
label all sequences from treatment-naive patients as ‘untreated’ but cannot exclude the
possibility that they might carry resistance mutations. However, due to their high
fitness cost some drug-resistance mutations tend to revert back to wild-type residue in
absence of therapy [84], suggesting that the protease sequence diversity due to
resistance mutations should decrease in cases of transmitted drug-resistance in
treatment-naive patients.
Table 1. Number of protease sequences in treated and untreated datasets.
Data downloaded from HIV Stanford database on September 17, 2013. The set of
sequences we use for our analysis is available from Dryad.
Year Untreated Treated
1998 376 680
1999 1145 946
2000 375 806
2001 476 575
2002 1982 464
2003 1237 3399
2004 2163 436
2005 1424 338
2006 1354 341
We also obtained longitudinal data (protease sequences collected from the same
patient after a time interval) that was available from HIV Stanford database for the
following: i) patient was untreated at first as well as second isolate collection (untreated
to untreated): 596 sequences, ii) patient untreated at first isolate collection but treated
with protease inhibitors at second isolate collection (untreated to treated): 395
sequences, iii) patient treated at both isolate collections (treated to treated): 921
sequences, and iv) patient treated at first isolate collection but untreated at second
isolate collection (treated to untreated): 153 sequences. The time between first and
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second isolate collections ranged from one month to a few years.
Information as a proxy for epistasis
Positive information between two sites indicates that the two sites are co-varying, but
co-variation is not the same as epistasis. To study the relationship between
informational co-variation and epistasis, we constructed a population-genetic two
alleles-two loci model that we solve using replicator-mutator equations. (The model can
be generalized to two loci with 20 alleles in a straightforward manner.)
We consider four genotypes (two alleles ‘A’ and ‘a’, at two loci): AA: (type 0, the
wild type), Aa (type 1), aA (type 2), and aa: (type 3) that undergo mutation with rate
µ per unit time (see Fig 6). The probability to find each of these genotypes in an
Figure 6. Rates of mutation between four different genotypes. The types are
denoted as 0=AA, 1=Aa, 2=aA, and 3=aa.
infinite population depends on the fitness and probabilities of the other genotypes. In a
discrete update scheme, the probability to find type i at time t+ 1 is related to the
same quantity at time t via
pt+10 = p
t
0
w0
w¯
F + µ
(
pt1w1 + p
t
2w2
w¯
)
+ µ2
pt3w3
w¯
(1)
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t
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pt0w0 + p
t
3w3
w¯
)
+ µ2
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pt0w0 + p
t
3w3
w¯
)
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(3)
pt+13 = p
t
3
w3
w¯
F + µ
(
pt1w1 + p
t
2w2
w¯
)
+ µ2
pt0w0
w¯
(4)
where w¯ is the mean fitness w¯ =
∑3
i=0 p
t
iwi, and F is the fidelity of replication
F = 1− 2µ− µ2. It is easy to show that ∑ pt+1i = 1 as long as ∑ pti = 1.
Equations (1-4) can be solved numerically iteratively, but alternatively the fixed
point (the pi in the limit t→∞) can be calculated by solving for the right eigenvector
of the associated Markov matrix. We investigate different fitness landscapes by varying
the fitness of the mutants, while the fitness of the wild-type is constant at w0 = 1. Fig 7
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shows equilibrium allele frequencies for a landscape where the double mutant has a
given fitness w3, while the intermediate genotypes have zero fitness (a valley-crossing
landscape with reciprocal sign epistasis).
Figure 7. Allele frequencies as fitness for type 3 (aa) is varied. In this
valley-crossing landscape, w0 is always 1 and w1 = w2 = 0. Plot shows allele frequencies
pi at mutation rate µ = 0.1 as a function of w3. The intermediate types aA and Aa
occur only at the rate of mutation as they have zero fitness.
Armed with the equilibrium probabilities pi, we can calculate the information
between loci as follows. First we define p(A) and p(a) for the first and second locus:
p(1)(A) = p0 + p1 , p
(1)(a) = 1− p0 − p1
p(2)(A) = p0 + p2 , p
(2)(a) = 1− p0 − p2 (5)
giving us the marginal entropies of the first and second locus
H(1) = −
∑
i=a,A
p(1)(i) log p(1)(i) ,
H(2) = −
∑
i=a,A
p(2)(i) log p(2)(i) . (6)
The joint entropy of both loci is then
H(1, 2) = −
∑
i=a,A
∑
j=a,A
p(1,2)(i, j) log p(1,2)(i, j) . (7)
where p(1,2)(i, j) is the joint probability to observe allele i at locus 1 and allele j at
locus 2.
The shared entropy (or information) is
I(1 : 2) = H(1) +H(2)−H(1, 2) . (8)
We can then relate this information to the epistasis between loci calculated as [25,80]
E = log(
w3
w0
)− log(w2
w0
)− log(w1
w0
) = log(
w3w0
w1w2
) (9)
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There are other ways of defining epistasis between loci (see, e.g., [77]), but the
qualitative relation between information and epistasis is not affected.
An extreme example occurs when w0 = w3 = 1 and w1 = w2 = 0, that is, when the
double mutant has the same fitness as the wild type, but the intermediate genotypes
have no fitness. In that case, it is necessary to cross a valley in the fitness landscape to
reach the double mutant aa. In this case of reciprocal sign epistasis [63], E =∞, and
I(1 : 2) = −(1− p0) log(1− p0)− (1− p3) log(1− p3) . (10)
If p0 = p3 = 0.5 (full equilibration) this extreme level of epistasis correspond to 1 bit of
information (the maximum possible). Fig. 8 shows the changes in genotype probabilities
and mutual information as the population adapts from a single-peak landscape (w0 = 1
and w1 = w2 = w3 ≈ 0) to a two-peak fitness landscape landscape (w0 = w3 = 1 and
w1 = w2 ≈ 0). Pairwise mutual information increases as the landscape becomes more
rugged. See S7 Text for simulations for a three-loci two-allele model that show that an
increase in the sum of mutual information coincides with the increase in the ruggedness
of the fitness landscape.
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Figure 8. Two-loci two-allele model. The left panel shows the fitness landscapes
and epistasis given by Eq. (9) in the first and second half of the simulation (updates
0-499: w0 = 1 and w1 = w2 = w3 = 10
−5 ≈ 0; updates 500-1000: w0 = w3 = 1 and
w1 = w2 = 10
−5 ≈ 0). The xy-plane shows the four genotypes while the z-axis shows
genotype fitness. The middle panel shows the genotype probabilities while the right
panel shows the mutual information during the course of the simulation. Note that the
increase in epistasis at the 500th update is reflected in the increase in mutual
information. The mutation rate was 0.1 and starting population frequencies were p0 = 1
and p1 = p2 = p3 = 0.
To study the general relationship between epistasis and information, we calculated
both epistasis and information starting with w0 = 1 (wild type fitness), and random
fitness values (between 0 and 1) for the single and double mutants w1, w2, and w3. The
equilibrium genotype probabilities were obtained by iterating the replicator-mutator
equations until they had stabilized (30,000 updates of genotype probabilities p0, p1, p2,
and p3 using equations (1-4), with starting genotype probabilities: p0 = 1,
p1 = p2 = p3 = 0). We find that the absolute value of epistasis |E| is positively
correlated with information (Spearman R = 0.497, p < 10−15, see Fig 9). It is clear that
information is a sufficient (but not necessary) condition for epistasis. Thus, high
information between two loci guarantees epistasis between those two loci, but there may
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Figure 9. Correlation between epistasis and information. Each point
corresponds to information and absolute value of epistasis calculated for one of the
10,000 combinations of w0, w1, w2, and w3. Here, w0 is always 1, and other fitness
values are uniformly randomly assigned between 0 and 1. The inset shows the
percentage of points with negligible information (<0.001 bits) as a function of epistasis.
be epistatically interacting loci that are missed when focusing only on information, as
some loci can interact epistatically without being informative about each other. In
addition, the direction of epistasis (the sign of E) cannot be determined solely from
information. To ascertain the fraction of epistatically interacting pairs that are missed
by an informational analysis, we examined pairs with information below a chosen cut-off
(here I < 0.001 bits). About 35% of all pairs have information below the threshold, but
only 28% of all pairs have non-vanishing epistasis at the same time (see inset in Fig 9,
which shows the distribution of epistasis among pairs with sub-threshold information).
This finding leads us to conclude that, at least in the simple model presented here, only
about 30% of epistatically interacting pairs are missed by using an information proxy.
Furthermore, the majority of those missed pairs have small epistasis, as evidenced by the
distribution of epistasis for those pairs with negligible information in the inset of Fig 9.
Information stored in HIV-1 protease
The information content of biomolecules can be estimated using information-theoretic
constructs [44,85,86]. Information content is different from sequence length: it can be
thought of as the amount of information that is stored in the protein sequence about
the cellular environment within which it functions (implying that it is contextual).
Information content can change when the environment changes even if the sequence
remains the same, and is thought to be a proxy for fitness [87]. Because a changed
environment usually translates into reduced information content (reflecting reduced
fitness), the virus seeks to recover the information and achieve previous fitness levels by
evolving drug resistance.
The total information content of a protein of length ` (taking into account all
correlations between residues) is given by (adapting a formula for the
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“multi-information” of ` events due to Fano [88]):
I` = Hmax −
∑`
i=1
Hi −
∑`
i<j
I(i : j) +
∑`
i<j<k
I(i : j : k)− . . .
 , (11)
where I(i : j) is the mutual information between two sites, I(i : j : k) the information
shared between three sites [88, p. 80], and so on. The terms not shown in Eq. (11) are
the higher-order corrections I(i : j : k : m) etc., up to I(i1 : i2 : ... : i`), with alternating
signs. Corrections due to interactions between three or more sites are expected to be
small, but cannot be estimated using the present data because the samples are too
small. Hmax is the sum of maximum entropy at every site, and thus is equal to
log2(20)× ` ≈ 4.32× ` bits, where ` is the sequence length [44].
We define the first- and second-order information estimates of (11) I1 and I2 as
follows:
I1 = Hmax −
l∑
i=1
Hi , (12)
I2 = I1 +
∑`
i<j
I(i : j) . (13)
Thus, I1 measures the information content of the protein without considering any
interactions among protein residues, and I2 includes information contained in pairwise
interactions between protein positions over and above I1, but ignores any other
higher-order interactions between residues. The second term in Eq. (13) is the sum of
pairwise mutual information for all pairs of residues in the protein. Note that if
information was only described by I1, mutations that provide resistance reduce the
information in the ensemble, as they increase sequence entropy. Achieving an increase in
total information must then occur via correlated mutations.
Changes in physicochemical properties of the residues
The site-wise changes in physicochemical properties of residues such as the iso-electric
point pI and residue weight in the protease are calculated by averaging their values
across the subsamples from each year and environment (treated and untreated). The
physicochemical properties of residues and their changes are discussed in S3 Text.
Finite-size corrections for entropy estimates
Small datasets do not correctly estimate the amino acid probabilities due to
dataset-dependent observed frequencies of residues: this introduces a bias in the entropy
and mutual information calculations (see, e.g., [89, 90]). Several priors and estimators
have been proposed to estimate entropies from undersampled probability
distributions [90], and our analysis suggests that a sample size of 300 with NSB
(Nemenman-Shafee-Bialek) entropy bias correction gives reliable estimates of entropy
and mutual information values (see S6 Text).
Since the number of treated and untreated protease sequences in our dataset is
different across years (Tab 1), we sampled (with replacement) 10 sets/year of 300
sequences each to account for sample size bias. We calculate bias-corrected entropies
and pairwise mutual information for the subsampled datasets, and report the average
values (along with ±1 SD). Because several protease sequences had gaps at the sequence
ends, we calculated the I1, I2, and sum of pairwise mutual information for a truncated
sequence length (from positions 15 to 90 instead of positions 1 to 99 of the protease
sequence, see S2 Fig).
PLOS 17/25
Statistical analysis of temporal trend of protein information
To compare the temporal trends of I1, I2, and sum of pairwise mutual information for
untreated and treated sequence data, we first fit linear regression models to the yearly
data using the R statistical analysis platform [91] and then determine if the slopes of the
regression models (for treated and untreated datasets) are significantly different or not.
Although the data used in this analysis is not longitudinal (protease sequences are
collected from different patients participating in different clinical trials/studies across
the years), the linear regression model is fit to the average values of the response
variables (I1, I2, and sum of pairwise mutual information) calculated by sampling ten
sets of 300 sequences each, and thus reflect the approximate temporal trends of the
response variables with respect to the two factors (untreated and treated).
Data Availability
The sequence data used, analysis scripts, and the iPython notebook for generating
figures are available in the Dryad repository: http://doi.org/10.5061/dryad.q66s5.
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Supporting Information
S1 Fig.
Change in per-site entropies in HIV-1 protease over time. Average entropy
change (compared to 1998) at every position of the HIV-1 protease in the untreated
(top panel) and treated (bottom panel) data sets. The size of the circles is proportional
to the entropy change, and blue marks an increase while red implies a decrease in
entropy at that site, compared to 1998 (the first year in our analysis). Site-specific
variation mostly increased across the protein even in the absence of treatment, but
decreased at some sites. In the treated data set, the entropy increased at most sites (in
particular starting in 2003) while some sites became less entropic.
S2 Fig.
Number of amino acids in each sampled set of 300 sequences for years
1998-2006. Gaps at the beginning and ends of the protease sequence imply uneven
sample size for positions ≥15 and ≤ 90, and thus the ends were truncated for
calculation of per-site entropies and pairwise mutual information. Filled circles
represent average number of residues in the sampled sets at each protease position and
error bars represent unit SD.
S1 Table
Protease Inhibitors (PIs) and the years they were approved by FDA.
S1 Text
Phylogenetic structure of protease sequence data.
S2 Text
Sequence Logos for HIV-1 protease sequences.
S3 Text
Changes in physicochemical properties at protease positions mirror
per-site entropy changes.
S4 Text
Changes in epistatic interactions in a longitudinal study.
S5 Text
Information between epistatic pairs in protease of treated and un-treated
subjects, for spatially close and distant epistatic residue pairs.
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S6 Text
Correction for sample-size bias in entropy and mutual information
estimates.
S7 Text
Three-loci two-allele model for understanding relationship between
epistasis and information
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